FDA calendar · July 2024 · built from SEC filings

PDUFA dates July 2024: FDA calendar and catalysts.

Updated Snapshot 20261116T112050ZBuilt

2 PDUFA dates fell in July 2024: TLX007 (Jul 2024), ZUNVEYL (July 27). The FDA calendar also recorded 43 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in July 2024

2 PDUFA target action dates in July 2024, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
Jul 2024Telix Pharmaceuticals LtdTLXTLX007SEC Form 10-K, filed 2025-02-24
July 27, 2024Alpha Cognition Inc.ACOGZUNVEYL (benzgalantamine)sec_s1, filed 2024-12-31

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

July 2024: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Jul 2024Month disclosedZORYVE (roflumilast)ARQTFDA approval—ApprovedSEC Form 10-Q
Jul 2024Month disclosedUNLOXCYT (cosibelimab)FBIONDA/BLA acceptedmetastatic or locally advanced cSCCCompletedSEC 8-K Exhibit 99.1
Jul 2024Month disclosedremestemcelMESONDA/BLA submissionchildren with SR-aGVHDCompletedSEC 8-K Exhibit 99.1
Jul 2024Month disclosedremestemcelMESONDA/BLA acceptedchildren with steroid-refractory acute graftCompletedSEC 8-K Exhibit 99.1
Jul 2024Month disclosedTranslarna™ (ataluren)PTCTNDA/BLA submissionnmDMDCompletedSEC Form 10-Q
Jul 2024Month disclosedSephience™ (sepiapterin)PTCTNDA/BLA submissionand adult patients with PKUCompletedSEC Form 10-Q
Jul 2024Month disclosedAUSTEDO (deutetrabenazine)TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
July 2, 2024Kisunla (donanemab-azbt)LLYFDA approvalTo treat Alzheimer’s diseaseApprovedFDA Novel Drug Approvals
July 8, 2024RyoncilMESONDA/BLA submission—CompletedSEC 8-K Exhibit 99.1
July 9, 2024ZORYVE (roflumilast)ARQTLabel expansion—ApprovedopenFDA Drugs@FDA
July 10, 2024Awiqli Flextouch (insulin icodec)NVOComplete Response Letter—CRL issuedFDA Complete Response Letters
July 11, 2024—BTAIQLabel expansion—ApprovedSEC Form 10-Q
July 17, 2024VOQUEZNA® (vonoprazan)PHATFDA approval—ApprovedSEC Form 10-Q
July 22, 2024KISQALI® (ribociclib)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
July 24, 2024LIVMARLI® (maralixibat)MIRMLabel expansion—ApprovedopenFDA Drugs@FDA
July 25, 2024Imfinzi® (durvalumab)AZNAdvisory committee—PositiveFDA advisory committee calendar
July 26, 2024—ACOGFDA approval—ApprovedSEC Form 10-K
July 26, 2024Zunveyl (benzgalantamine gluconate)ACOGFDA approval—ApprovedopenFDA Drugs@FDA
July 26, 2024Potassium Phosphates In 0.9% Sodium Chloride (potassium phosphate, dibasic; potassium phosphate, monobasic)AMRXFDA approval—ApprovedopenFDA Drugs@FDA
July 26, 2024—CEROComplete Response Letter—CRL issuedsec_s1
July 29, 2024ZUNVEYL (benzgalantamine)ACOGFDA approvalmild-to-moderate Alzheimer's diseaseApprovedsec_s1
July 30, 2024Darzalex Faspro (daratumumab and hyaluronidase-fihj)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
July 31, 2024DARZALEX (daratumumab)JNJLabel expansion—ApprovedopenFDA Drugs@FDA

July 2024: dated readouts

DateDrugCompanyEventIndicationStatusSource
Jul 2024Month disclosedbiosimilarALVOTopline readout—PositiveSEC 8-K Exhibit 99.1
Jul 2024Month disclosed—BNTXTopline readout—PositiveSEC 8-K Exhibit 99.1
Jul 2024Month disclosednebokitug (CM-101)CMMBTopline readout—Positivesec_424b
Jul 2024Month disclosed—HUMATopline readout—Met primary endpointSEC Form 10-Q
Jul 2024Month disclosedZYNYZ (retifanlimab)INCYTopline readout—PositiveSEC Form 10-Q
Jul 2024Month disclosedMytesi® (crofelemer)JAGXTopline readout—Missed primary endpointsec_424b
Jul 2024Month disclosedobicetrapibNAMSTopline readout—Met primary endpointSEC Form 10-K
July 1, 2024GV101OVIDTopline readoutcerebral cavernous malformationsPositiveSEC Form 10-Q
July 17, 2024ATH434ATHEInterim readoutadvanced MSAPositiveSEC 8-K Exhibit 99.1
July 25, 2024chemomabCMMBTopline readout—PositiveSEC 8-K Exhibit 99.1
July 28, 2024ATH434ATHETopline readoutmultiple system atrophyPositiveSEC 8-K Exhibit 99.1
July 30, 2024—IMNNTopline readout—PositiveSEC Form 10-Q
July 30, 2024—IMNNTopline readout—PositiveSEC Form 10-Q
July 30, 2024INM-901MTRIInterim readout—PositiveSEC Form 10-Q

July 2024: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Jul 2024Month disclosedINT230INTSTrial start—Completedsec_424b
Jul 2024Month disclosedenvudeucitinib (ESK-001)ALMSTrial start—CompletedSEC Form 10-Q
Jul 2024Month disclosedmivelsiranALNYTrial startCAA and in July 2026, weCompletedSEC Form 10-Q
Jul 2024Month disclosedCM5480CALCTrial start—CompletedSEC Form 10-Q
Jul 2024Month disclosedabiprubart (KPL-404)KNSATrial start—CompletedSEC Form 10-K
Jul 2024Month discloseddinger (SGR-3515)SDGRTrial startadvanced solid tumorsCompletedSEC Form 10-Q

3 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps July 2024. They are on each drug page and in the calendar API.

Questions

What PDUFA dates are in July 2024?

2 PDUFA dates fell in July 2024: TLX007 (Jul 2024), ZUNVEYL (July 27). The FDA calendar also recorded 43 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.